Myeloproliferative Neoplasms, 2011 Biology and Therapy Contemporary Hematology Series
Langue : Anglais
Coordonnateurs : Verstovsek Srdan, Tefferi Ayalew
This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.
Chapter 1 - Diagnosis and Classification of the BCR-ABL-negative Myeloproliferative Neoplasms.- Chapter 2 - Genetics of the Myeloproliferative Neoplasms.- Chapter 3 - Cytogenetic Findings in Classic Myeloproliferative Neoplasms.- Chapter 4 - Prognostic Factors in Classic Myeloproliferative Neoplasms.- Chapter 5 - Therapy of Polycythemia Vera and Essential Thrombocythemia.- Chapter 6 - Conventional and Investigational Therapy for Primary Myelofibrosis.- Chapter 7 - Hematopoietic Cell Transplantation for Myelofibrosis.- Chapter 8 - JAK2 Inhibitors as Therapy for Classic Myeloproliferative Neoplasms.- Chapter 9 - Blastic Transformation of Classic Myeloproliferative Neoplasms.- Chapter 10 - Eosinophilic Disorders: Differential Diagnosis and Management.- Chapter 11 - Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosi.
Provides the most up-to-date data on myeloproliferative neoplasms Explores the role of JAK2 and MPL mutations in pathogenesis and treatment Gives succinct, practical coverage of conventional and investigational therapies, including transplant Covers current classification and WHO-based diagnostic criterion Includes supplementary material: sn.pub/extras
Date de parution : 12-2012
Ouvrage de 230 p.
17.8x25.4 cm
Date de parution : 10-2010
Ouvrage de 230 p.
17.8x25.4 cm
Thèmes de Myeloproliferative Neoplasms :
Mots-clés :
Disorders; Eosinophilic; JAK2; Leukemia; MPL; Mastocytosis; Mutation; Myelofibrosis; Myeloid; Myeloproliferative; Neoplasms; Polycythemia; Throbocythemia
© 2024 LAVOISIER S.A.S.